$1.91
+0.11 (+6.11%)
Open$1.88
Previous Close$1.80
Day High$1.92
Day Low$1.79
52W High$11.87
52W Low$1.70
Volume—
Avg Volume85.6K
Market Cap7.61M
P/E Ratio—
EPS$-5.74
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+1,195.3% upside
Current
$1.91
$1.91
Target
$24.74
$24.74
$16.96
$24.74 avg
$28.19
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.58M | 4.80M | 3.77M |
| Net Income | 640.0K | 637.0K | 538.3K |
| Profit Margin | 14.0% | 13.3% | 14.3% |
| EBITDA | 1.20M | 1.08M | 968.7K |
| Free Cash Flow | 434.6K | 468.2K | 383.2K |
| Rev Growth | +11.7% | 0.0% | +15.1% |
| Debt/Equity | 0.17 | 0.18 | 0.18 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $254.31 | +0.38% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $360.55 | +0.62% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.33 | -1.21% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $499.65 | +1.69% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $631.81 | -0.17% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $293.52 | +0.74% | 69.3 | 39.97B |